Literature DB >> 9337499

Effects of adding behavioral treatment to opioid detoxification with buprenorphine.

W K Bickel1, L Amass, S T Higgins, G J Badger, R A Esch.   

Abstract

This trial assessed whether behavioral treatment improves outcome during a 26-week outpatient opioid detoxification. Thirty-nine opioid-dependent adults were assigned randomly to a buprenorphine dose-taper combined with either behavioral or standard treatment. Behavioral treatment included (a) a voucher incentive program for providing opioid-free urine samples and engaging in verifiable therapeutic activities and (b) the community reinforcement approach, a multicomponent behavioral treatment. Standard treatment included lifestyle counseling. Fifty-three percent of the patients receiving behavioral treatment completed treatment, versus 20% receiving standard treatment. The percentage of patients achieving 4, 8, 12, and 16 weeks of continuous opioid abstinence were 68, 47, 26, and 11 for the behavioral group and 55, 15, 5, and 0 for the standard group, respectively. Behavioral treatment improved outcomes during outpatient detoxification.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9337499     DOI: 10.1037//0022-006x.65.5.803

Source DB:  PubMed          Journal:  J Consult Clin Psychol        ISSN: 0022-006X


  40 in total

1.  The impact of enhanced incentives on vocational rehabilitation outcomes for dually diagnosed veterans.

Authors:  Charles E Drebing; E Alice Van Ormer; Christopher Krebs; Robert Rosenheck; Bruce Rounsaville; Lawrence Herz; Walter Penk
Journal:  J Appl Behav Anal       Date:  2005

2.  Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network.

Authors:  Lori J Ducharme; Hannah K Knudsen; Paul M Roman; J Aaron Johnson
Journal:  J Subst Abuse Treat       Date:  2007-02-22

3.  Opioid abstinence reinforcement delays heroin lapse during buprenorphine dose tapering.

Authors:  Mark K Greenwald
Journal:  J Appl Behav Anal       Date:  2008

Review 4.  Intangibility in intertemporal choice.

Authors:  Scott Rick; George Loewenstein
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-12-12       Impact factor: 6.237

5.  Optimizing Pregnancy Treatment Interventions for Moms (OPTI-Mom): A Pilot Study.

Authors:  Gerald T Cochran; Valerie Hruschak; Walitta Abdullah; Elizabeth Krans; Antoine B Douaihy; Stephanie Bobby; Rachel Fusco; Ralph Tarter
Journal:  J Addict Med       Date:  2018 Jan/Feb       Impact factor: 3.702

6.  Single- and cross-commodity discounting among cocaine addicts: the commodity and its temporal location determine discounting rate.

Authors:  Warren K Bickel; Reid D Landes; Darren R Christensen; Lisa Jackson; Bryan A Jones; Zeb Kurth-Nelson; A David Redish
Journal:  Psychopharmacology (Berl)       Date:  2011-04-14       Impact factor: 4.530

7.  Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment.

Authors:  William J Kowalczyk; Karran A Phillips; Michelle L Jobes; Ashley P Kennedy; Udi E Ghitza; Daniel A Agage; John P Schmittner; David H Epstein; Kenzie L Preston
Journal:  Am J Psychiatry       Date:  2015-03-17       Impact factor: 18.112

8.  A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.

Authors:  Walter Ling; Leslie Amass; Steve Shoptaw; Jeffrey J Annon; Maureen Hillhouse; Dean Babcock; Greg Brigham; Judy Harrer; Malcolm Reid; Joan Muir; Betty Buchan; Debbie Orr; George Woody; Jonathan Krejci; Douglas Ziedonis
Journal:  Addiction       Date:  2005-08       Impact factor: 6.526

9.  African American Caregivers and Substance Abuse in Child Welfare: Identification of Multiple Risk Profiles.

Authors:  Eusebius Small; Patricia L Kohl
Journal:  J Fam Violence       Date:  2012-07

10.  Brief buprenorphine detoxification for the treatment of prescription opioid dependence: a pilot study.

Authors:  Stacey C Sigmon; Kelly E Dunn; Gary J Badger; Sarah H Heil; Stephen T Higgins
Journal:  Addict Behav       Date:  2008-11-24       Impact factor: 3.913

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.